Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT: A phase-2 trial

P Gimsing, Ø Hjertner, N Abildgaard, N F Andersen, T G Dahl, H Gregersen, T W Klausen, U-H Mellqvist, O Linder, R Lindås, N Tøffner Clausen, S Lenhoff

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

10 Citationer (Scopus)

Fingeraftryk Dyk ned i forskningsemnerne om 'Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT: A phase-2 trial'. Sammen danner de et unikt fingeraftryk.

Medicin og biovidenskab